US04272N1028
US04272N1028
ArriVent BioPharma, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 824.92M EUR | 1.68B EUR | 1.05B EUR | 854.14M EUR |
Enterprise Value | 451.16M EUR | 1.52B EUR | 983.59M EUR | 808.61M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -4.32x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 2.2x | 4.58x | 3.23x | 2.78x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -- | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -10.85% | -8.81% | -12.86% | -10.84% |